Malta - English - Medicines Authority

central procurement & supplies unit - rifampicin - capsule - rifampicin 300 mg - antimycobacterials

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 300 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 600 mg - injection, powder for - excipient ingredients: sodium hydroxide; sodium formaldehyde sulfoxylate - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - rifampicin - hard capsule - rifampicin 300 mg - antimycobacterials

Kenya - English - Pharmacy and Poisons Board

sandoz private limited sandoz house, dr.annie besant road, worli, - rifampicin isoniazid pyrazinamide ethambutol… - film-coated tablet - rifampicin 150mg isoniazid 75mg pyrazinamide… - antimycobacterials: combinations of drugs for

Kenya - English - Pharmacy and Poisons Board

rifampicin - capsule - 150mg - rifampicin

United States - English - NLM (National Library of Medicine)

lantheus medical imaging, inc. - bicisate dihydrochloride (unii: b005p07v07) (bicisate - unii:3jxf0z0xoi) - bicisate dihydrochloride 0.9 mg - neurolite single photon emission computerized tomography (spect) is indicated as an adjunct to conventional ct or mri imaging in the localization of stroke in patients in whom stroke has already been diagnosed. neurolite is not indicated for assessment of functional viability of brain tissue. also, neurolite is not indicated for distinguishing between stroke and other brain lesions. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - bicisate dihydrochloride, quantity: 0.9 mg - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; water for injections - [99mtc]-bicisate scintigraphy is indicated in the evaluation and localisation of regional perfusion abnormalities in adult patients with the central nervous system disorders of stroke and dementia.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - fidaxomicin 200mg;   - film coated tablet - 200 mg - active: fidaxomicin 200mg   excipient: butylated hydroxytoluene hyprolose magnesium stearate microcrystalline cellulose opadry pregelatinised maize starch sodium starch glycolate - for the treatment of confirmed clostridium difficile infection (cdi) in adults